Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Stocks See Support from Lower Bond Yields and Positive Corporate News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.22%. US stocks today are mostly higher, with the S&P 500 climbing to a 1-month...

Up 58% YTD, is Eli Lilly Stock Still a Buy?

Up 58% YTD, is Eli Lilly Stock Still a Buy?

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

5 'Strong Buy' Stocks That Just Reported Killer Earnings

5 'Strong Buy' Stocks That Just Reported Killer Earnings

As the earnings season nears its close, here are five ‘Strong Buy’-rated stocks that delivered exceptional earnings results.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly has significantly outperformed the broader market over the past year, and Wall Street analysts are bullish about the stock’s prospects.

Stocks Rally Sharply on Positive US Labor Market News

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +2.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.76%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.06%. US stocks on Thursday settled sharply higher. Stocks rallied Thursday after US weekly initial...

Stock Market Today: Stocks Rally as Recession Fears Ease

Initial jobless claims fell more than expected last week, which helped calm fears of a slowing labor market.

Stocks Rally as Economic Concerns Ease and Chip Stocks Climb

The S&P 500 Index ($SPX ) (SPY ) today is up +1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.24%. US stocks are trading higher today after US weekly initial unemployment claims fell more...

inkl

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter

Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter

Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.

Stocks Climb as US Weekly Jobless Claims Ease Economic Concerns

Stocks Climb as US Weekly Jobless Claims Ease Economic Concerns

The S&P 500 Index ($SPX ) (SPY ) today is up +0.99%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.10%. US stocks are trading higher today after US weekly initial unemployment claims fell more...

Novo Nordisk cuts profit outlook after weaker sales of weight-loss drug Wegovy

Novo Nordisk cuts profit outlook after weaker sales of weight-loss drug Wegovy

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly

The Guardian - UK

1 Billionaire-Backed Penny Stock With 421% Upside

1 Billionaire-Backed Penny Stock With 421% Upside

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut

How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

Should You Buy These Stocks Before They Join The $1 Trillion Market Cap Club?

Should You Buy These Stocks Before They Join The $1 Trillion Market Cap Club?

Their strong fundamentals, brand strength, and drive to succeed could propel their stock higher.

3 Healthcare Innovators With Game-Changing Treatments

3 Healthcare Innovators With Game-Changing Treatments

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, rising R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks, Eli Lilly (LLY), Bristol-Myers (BMY), and Merck & Co. (MRK), which look poised for blockbuster…

Get all your
news in one place.

100's of premium titles.
One news app.

3 Leading S&P 500 Stocks Set to Climb Even Higher

As the stock market evolves, leading S&P 500 stocks like Eli Lilly and Company (LLY), Howmet Aerospace (HWM), and NetApp (NTAP) are well-positioned to capitalize on current market conditions and climb higher. Read on….

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

International Business Times UK

Jim Cramer Names Six Companies That May Enter the Trillion-Dollar Stock Club

In a recent episode of CNBC's Mad Money show, Jim Cramer named companies like Eli Lilly, Tesla, JPMorgan, and Walmart that could reach a $1 trillion market valuation.

Broadcasting & Cable

NBCU Plans Commercial-Free Hour During Olympic Opening Ceremonies

Coca-Cola, Delta, Eli Lilly, Toyota, Visa, Xfinity get ‘brought to you by’ mentions

Get all your
news in one place.

100's of premium titles.
One news app.

What You Need to Know Ahead of Eli Lilly's Earnings Release

As Eli Lilly gears up to release its second-quarter earnings next month, analysts project a double-digit bottom-line growth.

These weight-loss startups tell customers they can stop taking Ozempic or Wegovy and stay thin. Doctors disagree

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

International Business Times

Eli Lilly Weight Loss Drug Beats Ozempic In Head-to-head Study

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

The Independent UK

Ozempic maker slams Biden after the president accused the drug company of ‘ripping off’ US consumers

Remarks came after the president and Senator Bernie Sanders blasted the pharmaceutical giant for its ‘unconscionably high prices’

What Is Kisunla? Know All About New FDA-Approved Drug For Alzheimer's Disease

Kisunla manufactured by Eli Lilly could significantly slow cognitive decline in people with early symptomatic Alzheimer's disease, according to results of the company's clinical trials.

FDA Approves New Alzheimer's Drug To Slow Disease Progression

FDA approves Eli Lilly's donanemab for early Alzheimer's, offering hope for patients and caregivers. Treatment priced at 5 per vial.

The Guardian - US

FDA approves second Alzheimer’s drug that can slow onset of disease

Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease

1 … 19 20 21 22

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

The Associated Press

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

393,958 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play